Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: Frederick Langford who wrote (60744)	7/17/2002 10:19:12 AM
From: Ron	Read Replies (1) \| Respond to of 208838

Nice dip BLUD this morning on earnings. Conf call is at 11am. Watching for a bounce...

To: Frederick Langford who wrote (60744)	7/17/2002 10:20:43 AM
From: Dave Gore	Respond to of 208838

Fred, what do you think of LLL and also DPH in the auto sector? I am surprised at the weakness of the latter as all this 0% financing ought to help anyone supplying parts for autos. They guided strongly for several quarters ahead this morning.

To: Frederick Langford who wrote (60744)	7/17/2002 10:20:59 AM
From: DebtBomb	Respond to of 208838

Back in CSCO short. BRCM breaks 20. Who goes red next?? BRCD, close. MVSN red, PMCS, FFIV, close behind.

To: Frederick Langford who wrote (60744)	7/17/2002 10:25:13 AM
From: DebtBomb	Read Replies (2) \| Respond to of 208838

QLGC, LOD. Friggen SOX shooting straight down from the open. People ain't buying that BS gappa, IMO. Let's see if the SPX fills the intraday gap.

To: Frederick Langford who wrote (60744)	7/17/2002 10:38:58 AM
From: Dave Gore	Respond to of 208838

NOVN ($10.90) --- Moving up now; down 10 points (50%) in the last week; down in sympathy with WYE, but earnings exceeded expectations a few days ago. Announced as an ODOD (Oversold Disaster Of they Day) pick at $10.10 this morning on my thread about 10 minutes ago. You may want to check into it. NOVEN ANNOUNCES RECORD FINANCIAL RESULTS Net Income Up 193% Over 1999 Third Quarter Quarterly Revenues Increase 38% Over Prior Year Period MIAMI, FL., November 1, 2000 - Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced record financial results for the quarter and nine-month period ended September 30, 2000. For the quarter, Noven reported net income of $3.6 million, or diluted earnings of $.15 per share, compared to $1.2 million, or diluted earnings of $.06 per share, for the third quarter of 1999. Revenues were $11.2 million, compared to $8.1 million for the same quarter in 1999. Noven increased its research and development spending in the third quarter to $3.3 million from $1.6 million in the third quarter of 1999, most of which related to clinical trials for Noven's MethyPatch™ transdermal methylphenidate delivery system for Attention Deficit Hyperactivity Disorder, which is in Phase III clinical trials. For the first nine months of 2000, Noven reported net income of $8.9 million, or diluted earnings of $.39 per share, compared to $2.9 million, or diluted earnings of $.13 per share, for the first nine months of 1999. Revenues were $31.2 million compared to $23.0 million for the same period in 1999. Research and development expense for the first nine months of 2000 was $8.7 million, compared to $4.7 million in the same period in 1999.